Epidermal growth factor receptor based active targeting: a paradigm shift towards advance tumor therapy

Akhter, Md. Habban; Madhav, Nv Sateesh; Ahmad, Javed

doi:10.1080/21691401.2018.1481863

Cited by 50 publications

(18 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The current study aimed to design, optimize, and develop α-MNG-PLGA NPs and analyze the skin permeation and retention of the drug from nanocarriers within the distinguished layer of animal skin [ 23 , 24 ]. The formulation was tested in a melanoma cell line for its anticancer and antioxidant properties.…”

Section: Introductionmentioning

confidence: 99%

Development, Characterization, and Evaluation of α-Mangostin-Loaded Polymeric Nanoparticle Gel for Topical Therapy in Skin Cancer

Alhakamy

Neamatallah

et al. 2021

Gels

View full text Add to dashboard Cite

The aim of this study was to prepare and evaluate α-mangostin-loaded polymeric nanoparticle gel (α-MNG-PLGA) formulation to enhance α-mangostin delivery in an epidermal carcinoma. The poly (D, L-lactic-co-glycolic acid) (PLGA) nanoparticles (NPs) were developed using the emulsion–diffusion–evaporation technique with a 3-level 3-factor Box–Behnken design. The NPs were characterized and evaluated for particle size distribution, zeta potential (mV), drug release, and skin permeation. The formulated PLGA NPs were converted into a preformed carbopol gel base and were further evaluated for texture analysis, the cytotoxic effect of PLGA NPs against B16-F10 melanoma cells, and in vitro radical scavenging activity. The nanoscale particles were spherical, consistent, and average in size (168.06 ± 17.02 nm), with an entrapment efficiency (EE) of 84.26 ± 8.23% and a zeta potential of −25.3 ± 7.1 mV. Their drug release percentages in phosphate-buffered solution (PBS) at pH 7.4 and pH 6.5 were 87.07 ± 6.95% and 89.50 ± 9.50%, respectively. The release of α-MNG from NPs in vitro demonstrated that the biphasic release system, namely, immediate release in the initial phase, was accompanied by sustained drug release. The texture study of the developed α-MNG-PLGA NPs gel revealed its characteristics, including viscosity, hardness, consistency, and cohesiveness. The drug flux from α-MNG-PLGA NPs gel and α-MNG gel was 79.32 ± 7.91 and 16.88 ± 7.18 µg/cm2/h in 24 h, respectively. The confocal study showed that α-MNG-PLGA NPs penetrated up to 230.02 µm deep into the skin layer compared to 15.21 µm by dye solution. MTT assay and radical scavenging potential indicated that α-MNG-PLGA NPs gel had a significant cytotoxic effect and antioxidant effect compared to α-MNG gel (p < 0.05). Thus, using the developed α-MNG-PLGA in treating skin cancer could be a promising approach.

show abstract

Section: Introductionmentioning

confidence: 99%

Development, Characterization, and Evaluation of α-Mangostin-Loaded Polymeric Nanoparticle Gel for Topical Therapy in Skin Cancer

Alhakamy

Neamatallah

et al. 2021

Gels

View full text Add to dashboard Cite

show abstract

“…19 Briefly, the passively targeted NPs release substantial part of therapeutics to tumor tissue and get accumulated owing to the EPR effect which mediated passive-targeting approach. 20,21 To avail this technology, nanomedicine-based strategies are the most prominent of therapeutic approaches in cancer treatment. 22,23 Natural products have been proved to play a key role in suppressing the cancer proliferation via different mechanisms in recent years.…”

Section: Introductionmentioning

confidence: 99%

Emodin-Conjugated PEGylation of Fe3O4 Nanoparticles for FI/MRI Dual-Modal Imaging and Therapy in Pancreatic Cancer

Ren¹,

Song²,

Tian³

et al. 2021

IJN

View full text Add to dashboard Cite

“…HER1 and HER2 are clinically validated targets in several cancers, such as squamous cell carcinoma of the head and neck [23], colorectal [24], breast [25], gastric [26], brain [27], and non-small cell lung cancers [28]. And growing evidence suggests that HER3 will prove to be a clinically relevant target as well [8].…”

Section: Discussionmentioning

confidence: 99%

Working together for the family: determination of HER oncogene co-amplifications in breast cancer

et al. 2020

View full text Add to dashboard Cite

HER2 is a well-studied tyrosine kinase (TK) membrane receptor which functions as a therapeutic target in invasive ductal breast carcinomas (IDC). The standard of care for the treatment of HER2-positive breast is the antibody trastuzumab. Despite specific treatment unfortunately, 20% of primary and 70% of metastatic HER2 tumors develop resistance. HER2 belongs to a gene family, with four members (HER1-4) and these members could be involved in resistance to anti-HER2 therapies. In this study we designed a probemix to detect the amplification of the four HER oncogenes in a single reaction. In addition, we developed a protocol based on the combination of MLPA with ddPCR to detect the tumor proportion of co-amplified HERs. On 111 IDC, the HER2 MLPA results were validated by FISH (Adjusted r 2 = 0,91, p < 0,0001), CISH (Adjusted r 2 = 0,938, p < 0,0001) and IHC (Adjusted r 2 = 0,31, p < 0,0001). HER1-4 MLPA results were validated by RT-qPCR assays (Spearman Rank test p < 0,05). Of the 111 samples, 26% presented at least one HER amplified, of which 23% showed coamplifications with other HERs. The percentage of cells with HER2 co-amplified varied among the tumors (from 2-72,6%). Independent in-silico findings show that the outcome of HER2+ patients is conditioned by the status of HER3 and HER4. Our results encourage further studies to investigate the relationship with patient's response to single or combined treatment. The approach could serve as proof of principle for other tumors in which the HER oncogenes are involved.

show abstract

Epidermal growth factor receptor based active targeting: a paradigm shift towards advance tumor therapy

Cited by 50 publications

References 48 publications

Development, Characterization, and Evaluation of α-Mangostin-Loaded Polymeric Nanoparticle Gel for Topical Therapy in Skin Cancer

Development, Characterization, and Evaluation of α-Mangostin-Loaded Polymeric Nanoparticle Gel for Topical Therapy in Skin Cancer

Emodin-Conjugated PEGylation of Fe3O4 Nanoparticles for FI/MRI Dual-Modal Imaging and Therapy in Pancreatic Cancer

Working together for the family: determination of HER oncogene co-amplifications in breast cancer

Contact Info

Product

Resources

About